In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2011 transferred altogether 102,900 Orion Corporation B-shares held by the company as a share reward for 2010 to the persons employed by the Orion Group and belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 24 March 2010. The price per share of the transferred shares is EUR 16.7488, which is the volume weighted average quotation of the Orion Corporation B-share on 1 March 2011. Accordingly, the total transaction price of the transferred shares is EUR 1,723,451.52.
After the share transfer, the total number of own B-shares held by Orion Corporation is 413,754.
Orion Corporation has informed about the Share-based Incentive Plan in a stock exchange release on 18 February 2010.
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Orionintie 1A, 02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.